GeoVax Presents Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine
04 avr. 2024 12h30 HE
|
GeoVax, Inc.
Presentation Made During the 24th Annual World Vaccine Congress ATLANTA, GA, April 04, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company...
GeoVax to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress
28 mars 2024 09h00 HE
|
GeoVax, Inc.
ATLANTA, GA, March 28, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious...
GeoVax Announces Gedeptin® Patient Enrollment Closure for Phase 1/2 Clinical Trial Among Advanced Head and Neck Cancer Patients
04 janv. 2024 09h00 HE
|
GeoVax, Inc.
Therapy Demonstrated Safety, Stabilization/Shrinkage of Treated Tumors Expanded Development for Monotherapy and Combination Therapy Anticipated ATLANTA, GA, Jan. 04, 2024 (GLOBE NEWSWIRE) -- via...
GeoVax Expands Rights Under NIH COVID-19 License to Include Mpox and Smallpox
19 déc. 2023 09h00 HE
|
GeoVax, Inc.
ATLANTA, GA, Dec. 19, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious...
GeoVax to Participate in Upcoming December Investor Events
29 nov. 2023 09h00 HE
|
GeoVax, Inc.
ATLANTA, GA, Nov. 29, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious...
Progress on GeoVax’s Universal Coronavirus Vaccine Candidate, GEO-CM02, Presented at Vaccines Summit 2023
14 nov. 2023 09h00 HE
|
GeoVax, Inc.
Single-Dose Protection Demonstrated Against Multiple SARS-CoV-2 Variants ATLANTA, GA, Nov. 14, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company...
GeoVax to Report Third Quarter 2023 Financial Results and Provide Corporate Update on November 8, 2023
31 oct. 2023 09h00 HE
|
GeoVax, Inc.
GeoVax to Host Conference Call at 4:30 PM ET ATLANTA, GA, Oct. 31, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing...
GeoVax to Participate in Upcoming November Investor and Industry Events
25 oct. 2023 09h00 HE
|
GeoVax, Inc.
ATLANTA, GA, Oct. 25, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious...
GeoVax Update: Clinical and Operational Progress Toward Transformative Opportunities
24 oct. 2023 09h00 HE
|
GeoVax, Inc.
ATLANTA, GA, Oct. 24, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious...
GeoVax Secures Multi-Product License for ProBioGen's AGE1.CR.pIX® Suspension Cell Line to Bolster MVA-Based Vaccine Development
26 sept. 2023 09h00 HE
|
GeoVax, Inc.
ATLANTA, GA and BERLIN, Germany, Sept. 26, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing vaccines and immunotherapies against...